Characteristics of familial isolated pituitary adenomas

References

• Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer101(3), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Davis JR, Farrell WE, Clayton RN. Pituitary tumours. Reproduction121(3), 363–371 (2001).
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab.91, 4769–4775 (2006).
   PubMed Web of Science ®Google Scholar
• Asa SL, Ezzat S. Genetics and proteomics of pituitary tumors. Endocrine28(1), 43–47 (2005).
   Google Scholar
• Daly AF, Jaffrain-Rea ML, Beckers A. Clinical and genetic features of familial pituitary adenomas. Horm. Metab. Res.37(6), 347–354 (2005).
   Google Scholar
• Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol.4(3), 205–211 (1987).
   PubMed Web of Science ®Google Scholar
• Daly AF, Jaffrain-Rea ML, Ciccarelli A et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab.91(9), 3316–3323 (2006).
   PubMed Web of Science ®Google Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science312(5777), 1228–30 (2006).
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab.92(5), 1891–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Lee Burns A, Sukhodolets KE et al. Molecular pathology of the MEN1 gene. Ann. NY Acad. Sci.1014, 189–198 (2004).
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science276(5311), 404–407 (1997).
   PubMed Web of Science ®Google Scholar
• Hai N, Aoki N, Shimatsu A, Mori T, Kosugi S. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin. Endocrinol. (Oxford)52(4), 509–518 (2000).
   Google Scholar
• Burgess JR, Nord B, David R et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN1). Clin. Endocrinol. (Oxford)53(2), 205–211 (2000).
   Google Scholar
• Scacheri PC, Davis S, Odom DT et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet.2(4), e51 (2006).
   PubMedGoogle Scholar
• Agarwal SK, Impey S, McWeeney S et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia9(2), 101–107 (2007).
   PubMedGoogle Scholar
• Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl Acad. Sci. USA98(3), 1118–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol.17(9), 1880–1892 (2003).
   PubMed Web of Science ®Google Scholar
• Biondi CA, Gartside MG, Waring P et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol. Cell. Biol.24(8), 3125–3131 (2004).
   PubMedGoogle Scholar
• Zhuang Z, Vortmeyer AO, Pack S et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res.57(21), 4682–4686 (1997).
   PubMed Web of Science ®Google Scholar
• Vergès B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France–Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab.87(2), 457–465 (2002).
   PubMed Web of Science ®Google Scholar
• Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J. Intern. Med.253(6), 599–605 (2003).
   PubMed Web of Science ®Google Scholar
• Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation and endocrine overactivity. Mayo Clin. Proc.61, 165–172 (1985).
   Google Scholar
• Casey M, Mah C, Merliss AD et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation98, 2560–2566 (1998).
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab.86(9), 4041–4046 (2001).
   PubMed Web of Science ®Google Scholar
• Griffin KJ, Kirschner LS, Matyakhina L et al. Down-regulation of regulatory subunit Type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res.64(24), 8811–5 (2004).
   PubMed Web of Science ®Google Scholar
• Griffin KJ, Kirschner LS, Matyakhina L et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours. J. Med. Genet.41(12), 923–31 (2004).
   PubMed Web of Science ®Google Scholar
• Stergiopoulos SG, Stratakis CA. Human tumors associated with Carney complex and germline PPKAR1A mutations: a protein kinase A disease! FEBS Lett.546, 59–64 (2003).
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histological studies of somatomammotropic tumors in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J. Clin. Endocrinol. Metab.85(10), 3860–3865 (2000).
   PubMed Web of Science ®Google Scholar
• Frohman LA, Eguchi K. Familial acromegaly. Growth Horm. IGF Res.14(Suppl. A), S90–S96 (2004).
   Google Scholar
• Yamada S, Yoshimoto K, Sano T et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab.82(1), 239–242 (1997).
   Google Scholar
• Lucio-Camelo DC, Une KN, Ferreira RES et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur. J. Endocrinol.150, 643–648 (2004).
   Google Scholar
• Valdes-Socin H, Poncin J, Stevens V, Stevenaert A, Beckers A. Adenomes hypophysaires familiaux isoles non lies avec la mutation somatique NEM-1. Suivi de 27 patients. Ann. Endocrinol. (Paris)61(4), 301 (2000).
   Google Scholar
• Beckers A. Familial isolated pituitary adenomas. In: The Ninth International Workshop on Multiple Endocrine Neoplasia (MEN2004). J. Intern. Med.255(6), 696–730 (2004).
   Google Scholar
• Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev.26(5), 615–661 (2005).
   PubMedGoogle Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary8(1), 3–6 (2005).
   PubMedGoogle Scholar
• Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin. Endocrinol. (Oxford)66(4), 499–502 (2007).
   PubMed Web of Science ®Google Scholar
• Toledo RA, Lourenco DM Jr, Liberman B et al. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J. Clin. Endocrinol. Metab.92(5), 1934–1937 (2007).
   PubMed Web of Science ®Google Scholar
• Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S. AIP variants in sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.91(12), 5126–5129 (2006).
   PubMed Web of Science ®Google Scholar
• Barlier A, Vanbellinghen JF, Daly AF et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.92(5), 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA104(10), 4101–4105 (2007).
   PubMed Web of Science ®Google Scholar
• Cazabat L, Libe R, Perlemoine K et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol..157(1), 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Karhu A, Winqvist R et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br. J. Cancer96(2), 352–356 (2007).
   Web of Science ®Google Scholar
• Carver LA, LaPres JJ, Jain S, Dunham EE, Bradfield CA. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem.273(50), 33580–33587 (1998).
   PubMed Web of Science ®Google Scholar
• Petrulis JR, Perdew GH. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. Biol. Interact.141(1–2), 25–40 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer BK, Petrulis JR, Perdew GH. Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2. Cell Stress Chaperones5(3), 243–254 (2000).
   Web of Science ®Google Scholar
• Bell DR, Poland A. Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J. Biol. Chem.275(46), 36407–36414 (2000).
   PubMed Web of Science ®Google Scholar
• Meyer BK, Perdew GH. Characterization of the AhR–hsp90–XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry38(28), 8907–8917 (1999).
   PubMed Web of Science ®Google Scholar
• Lees MJ, Peet DJ, Whitelaw ML. Defining the role for XAP2 in stabilization of the dioxin receptor. J. Biol. Chem.278(38), 35878–35888 (2003).
   PubMed Web of Science ®Google Scholar
• Lee K, Burgoon LD, Lamb L et al. Identification and characterization of genes susceptible to transcriptional cross-talk between the hypoxia and dioxin signaling cascades. Chem. Res. Toxicol.19(10), 1284–1293 (2006).
   PubMed Web of Science ®Google Scholar
• Bolger GB, Peden AH, Steele MR et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem.278(35), 33351–33363 (2003).
   PubMed Web of Science ®Google Scholar
• de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA, Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem.4(18), 13656–13663 (2007).
   Google Scholar
• Gueorguiev M, Quinton R, Chapple R et al. The role of AIP in familial acromegaly. The Endocrine Society 89th Annual Congress, Toronto, Canada, June 2–5, 2007 (OR15–2).
   Google Scholar